{"id":482137,"date":"2020-05-04T06:52:02","date_gmt":"2020-05-04T06:52:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=482137"},"modified":"2020-05-04T06:52:02","modified_gmt":"2020-05-04T06:52:02","slug":"acute-respiratory-distress-syndrome-ards-market-analysis-market-size-epidemiology-leading-companies-and-competitive-analysis-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/acute-respiratory-distress-syndrome-ards-market-analysis-market-size-epidemiology-leading-companies-and-competitive-analysis-delveinsight_482137.html","title":{"rendered":"Acute Respiratory Distress Syndrome (ARDS) Market Analysis, Market Size, Epidemiology, Leading Companies and Competitive Analysis DelveInsight"},"content":{"rendered":"
\"Acute<\/a><\/p>\n
\n
\u201cAcute Respiratory Distress Syndrome (ARDS) – Market Insights, Epidemiology & Market Forecast\u20132030\u201d<\/div>\n<\/div>\n<\/div>\n

DelveInsight has launched a new report on “Acute Respiratory Distress Syndrome (ARDS) – Market Insights, Epidemiology & Market Forecast–2030<\/a><\/strong>”.<\/p>\n

 <\/p>\n

Some facts of the report:<\/strong><\/p>\n

    \n
  1. Total incident population of ARDS in the 7MM observed to be 815,490 in 2017 for the study period 2017– 2030.<\/li>\n
  2. DelveInsight’s estimates show higher incidence of ARDS in the United States with an estimated number of 497,947 cases in 2017<\/li>\n
  3. Among the EU-5 countries, Germany had the highest incident population of ARDS with 148,302 cases.<\/li>\n
  4. Among the EU-5 countries, Spain had the lowest incident population of 20,839 in 2017.<\/li>\n<\/ol>\n

     <\/p>\n

    Request for Sample Page: https:\/\/www.delveinsight.com\/sample-request\/acute-respiratory-distress-syndrome-ards-market<\/a><\/strong><\/p>\n

     <\/strong><\/p>\n

    Key Benefits of the Report:<\/strong><\/p>\n

      \n
    1. Acute Respiratory Distress Syndrome Market report covers a descriptive overview and comprehensive insight of the Acute Respiratory Distress Syndrome epidemiology and Acute Respiratory Distress Syndrome market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)<\/li>\n
    2. Acute Respiratory Distress Syndrome market report provides insights on the current and emerging therapies.<\/li>\n
    3. Acute Respiratory Distress Syndrome market report provides a global historical and forecasted market covering drug outreach in 7 MM.<\/li>\n
    4. Acute Respiratory Distress Syndrome market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Acute Respiratory Distress Syndrome market.<\/li>\n<\/ol>\n

       <\/p>\n

      Request for Sample Page: https:\/\/www.delveinsight.com\/sample-request\/acute-respiratory-distress-syndrome-ards-market<\/a><\/strong><\/p>\n

       <\/strong><\/p>\n

      Acute respiratory distress syndrome (ARDS) is a rapidly progressive disease occurring in critically ill patients. The main complication in ARDS is that fluid leaks into the lungs making breathing difficult or impossible.<\/p>\n

      The causes of ARDS are divided into two categories: direct or indirect injuries to the lung. Some of the direct injuries to the lung include pneumonia, aspiration, trauma, and others. Whereas the indirect injuries to the lung include inflammation of the pancreas, severe infection (also known as sepsis), blood transfusions, burns, and medication reactions.<\/p>\n

      The few symptoms of ARDS are, shortness of breath, cough, and fever. In some cases, those with ARDS also have fast heart rates and rapid breathing. Occasionally, patients of ARDS experience chest pain, especially during inhalation. Some patients also experience bluish coloring of nails and lips due to the severely decreased oxygen levels in the blood. There are several risk-factors that may escalate the risk for ARDS. This involves obesity, alcohol abuse, chemotherapy, low-protein in blood.<\/p>\n

       <\/p>\n

      “The highest number of incident cases were assessed for ARDS due to pneumonia, in all the 7MM countries, except the United Kingdom, in which Sepsis was the primary risk factor for ARDS”<\/em><\/strong><\/p>\n

       <\/strong><\/p>\n

      Request for Sample Page: https:\/\/www.delveinsight.com\/sample-request\/acute-respiratory-distress-syndrome-ards-market<\/a><\/strong><\/p>\n

       <\/strong><\/p>\n

       <\/strong><\/p>\n

      The launch of the emerging therapies is expected to significantly impact Acute respiratory distress syndrome treatment scenario in the upcoming years:-<\/p>\n

      Drugs covered:<\/strong><\/p>\n